Fasinumab
As of the edition of 20 October 2026, Fasinumab is an antibody: went quiet in 2021; acts on NGF.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2021
- Kind
- Antibody
- Registered trials
- 16, 5 stopped early
- Disease areas
- Bones, joints and muscles; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Fasinumab.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| NGF | Beta-nerve growth factor | P01138 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 7 | 3 | 0 | 4 |
| Phase 3 | 7 | 6 | 0 | 1 |
| All trials | 16 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Regeneron | Lead sponsor of trials | 2015 to now |
| Tanabe Pharma | Lead sponsor of trials | 2017 to now |